Mega Lifesciences PCL

Mega Lifesciences maintains a strong liquidity position, with a current ratio of 2.23 and a price-to-book ratio of 2.94, indicating a relatively high asset base relative to equity. The company's free cash flow of 207.5 million THB and operating cash flow of 2.77 billion THB support its ability to fund operations and reinvest. However, the company has a negative net cash position after subtracting total debt, which introduces some liquidity risk. Profitability metrics show a return on equity (ROE) of 18.72% and a return on assets (ROA) of 12.13%, both above the typical thresholds for the pharmaceutical industry. The gross profit margin is 52.2%, and the operating margin is 20.8%, suggesting efficient cost management and pricing power. The company's revenue is concentrated in its domestic market, with a significant portion derived from Thailand. While it has expanded into other Southeast Asian countries, the geographic diversification remains limited, exposing the company to regional economic and regulatory risks. Looking ahead, the company is projected to grow revenue by 5.3% in the current fiscal year and 4.1% in the next, driven by expansion in its generic drug portfolio and increased market penetration in key therapeutic areas. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company has not issued additional shares recently, and its diluted share count remains unchanged at 871.87 million shares. However, the negative net cash position and the presence of long-term debt (683.5 million THB) could pressure liquidity in the event of a downturn. Recent events include a 10-K filing that outlines strategic initiatives to expand into new therapeutic areas and a Q4 earnings call where management emphasized cost optimization and R&D investment. Analysts have issued a mean price target of 39.33 THB, with a median of 39.30 THB, and a mean recommendation of 2.29 (leaning toward buy).